On July 22, 2010, Pathway testified before the U.S. House of Representatives’ Committee on Energy and Commerce. At this Congressional hearing, the U.S. Government Accountability Office (GAO) released its report titled, “Direct-to-Consumer Genetic Tests: Misleading Test Results Are Further Complicated by Deceptive Marketing and Other Questionable Practices.” This report, coupled with the testimony of Gregory Kutz, Managing Director of Forensic Audits and Special Investigations for GAO, unfairly portrayed Pathway Genomics along with 23andme and Navigenics as providing genetic reports directly to consumers in a manner that GAO considered inaccurate and irresponsible.

While we acknowledge that the Congressional hearing and the GAO report did highlight areas of legitimate concern to the entire genetic testing industry, we have a written a response that seeks to correct the record on several serious flaws and inaccuracies in the GAO report and testimony. Click the image below to read Pathway Genomics’ official response to the GAO report.

Comments are closed.